BioCentury | Jul 11, 2016
Finance

Shedding red

...FDA to issue a complete response letter Helsinn Healthcare S.A. / Zealand Pharma A/S (CSE:ZEAL) Elsiglutide...
BioCentury | May 9, 2016
Clinical News

Elsiglutide: Phase IIb data

...Phase IIb trial in 497 colorectal cancer patients receiving 5-fluorouracil (5-FU) showed that once-daily subcutaneous elsiglutide...
...cycle of chemotherapy vs. placebo. Patients received placebo or subcutaneous 10, 20 or 40 mg elsiglutide...
...Helsinn Healthcare S.A. , Lugano, Switzerland Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: Elsiglutide ( ZP1846...
BioCentury | May 5, 2016
Clinical News

Helsinn's elsiglutide misses in Phase IIb trial

...Helsinn Healthcare S.A. (Lugano, Switzerland) said elsiglutide ( ZP1846 ) missed the primary endpoint in a...
...a Phase IIb study to prevent chemotherapy-induced diarrhea in colorectal cancer patients. The company said elsiglutide...
...proportion of patients with diarrhea grade 2 and higher during the first cycle of chemotherapy. Elsiglutide's...
BioCentury | Feb 16, 2015
Clinical News

Elsiglutide: Phase IIb started

...a double-blind, placebo-controlled, international Phase IIb trial to evaluate 10, 20 and 40 mg subcutaneous elsiglutide...
...and commercialize the product from Zealand, which retains an option to obtain commercial rights to elsiglutide...
...Helsinn Healthcare S.A. , Lugano, Switzerland Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: Elsiglutide ( ZP1846...
BioCentury | Mar 12, 2012
Clinical News

Elsiglutide: Phase IIa started

...Helsinn began a double-blind, placebo-controlled, European Phase IIa trial evaluating 24 mg subcutaneous elsiglutide once daily...
...colorectal cancer receiving 5-fluorouracil (5-FU)-based chemotherapy. Helsinn has exclusive, worldwide rights to develop and commercialize elsiglutide...
...Helsinn Healthcare S.A. , Pazzallo-Lugano, Switzerland Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: Elsiglutide ( ZP1846...
BioCentury | Jan 9, 2012
Company News

Helsinn, Zealand Pharma deal

...a 2008 deal granting Helsinn an exclusive, worldwide license to develop and commercialize elsiglutide ( ZP1846...
BioCentury | Dec 20, 2010
Company News

Helsinn, Zealand Pharma deal

...Helsinn under a 2008 deal granting Helsinn an exclusive, worldwide license to develop and commercialize ZP1846...
BioCentury | May 31, 2010
Finance

Performance Counts

...2003. The company is also developing a couple of SIP-modified glucagon-like peptide GLP-2 analog peptides, ZP1846...
...against chemotherapy-induced diarrhea and inflammatory bowel disease (IBD), respectively. Both are in Phase I testing. ZP1846...
BioCentury | Dec 15, 2008
Company News

Helsinn, Zealand Pharma deal

...Zealand granted Helsinn an exclusive, worldwide license to develop and commercialize ZP1846 in all indications. The...
...manufacturing and commercialization. Zealand is eligible for milestones and royalties, and retains rights to market ZP1846...
BioCentury | Dec 2, 2008
Company News

Helsinn in-licenses Zealand's ZP1846

...Zealand (Glostrup, Denmark) granted Helsinn (Pazzallo, Switzerland) an exclusive, worldwide license to develop and commercialize ZP1846...
Items per page:
1 - 10 of 11